HK1089667A1 - Cancer combination therapy comprising azd2171 and zd1839 - Google Patents

Cancer combination therapy comprising azd2171 and zd1839

Info

Publication number
HK1089667A1
HK1089667A1 HK06110069.9A HK06110069A HK1089667A1 HK 1089667 A1 HK1089667 A1 HK 1089667A1 HK 06110069 A HK06110069 A HK 06110069A HK 1089667 A1 HK1089667 A1 HK 1089667A1
Authority
HK
Hong Kong
Prior art keywords
azd2171
human
combination therapy
cancer
antiangiogenic
Prior art date
Application number
HK06110069.9A
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1089667A1 publication Critical patent/HK1089667A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
HK06110069.9A 2003-07-10 2006-09-11 Cancer combination therapy comprising azd2171 and zd1839 HK1089667A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316127.0A GB0316127D0 (en) 2003-07-10 2003-07-10 Combination therapy
PCT/GB2004/002944 WO2005004872A1 (en) 2003-07-10 2004-07-08 Cancer combination therapy comprising azd2171 and zd1839

Publications (1)

Publication Number Publication Date
HK1089667A1 true HK1089667A1 (en) 2006-12-08

Family

ID=27741907

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06110069.9A HK1089667A1 (en) 2003-07-10 2006-09-11 Cancer combination therapy comprising azd2171 and zd1839

Country Status (24)

Country Link
US (2) US20060167024A1 (zh)
EP (1) EP1653964B1 (zh)
JP (1) JP2007526888A (zh)
KR (1) KR20060033785A (zh)
CN (1) CN100415236C (zh)
AT (1) ATE409039T1 (zh)
AU (1) AU2004255024B2 (zh)
BR (1) BRPI0412408A (zh)
CA (1) CA2531620C (zh)
DE (1) DE602004016754D1 (zh)
DK (1) DK1653964T3 (zh)
ES (1) ES2313033T3 (zh)
GB (1) GB0316127D0 (zh)
HK (1) HK1089667A1 (zh)
HR (1) HRP20080597T3 (zh)
IL (1) IL172683A0 (zh)
MX (1) MXPA06000412A (zh)
NO (1) NO20056170L (zh)
NZ (1) NZ544270A (zh)
PL (1) PL1653964T3 (zh)
PT (1) PT1653964E (zh)
SI (1) SI1653964T1 (zh)
WO (1) WO2005004872A1 (zh)
ZA (1) ZA200600184B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
CA2558346A1 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
US20090176731A1 (en) * 2005-07-06 2009-07-09 Stephen Robert Wedge Combination therapy of cancer with azd2171 and gemcitabine
WO2007071970A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of azd2171 and pemetrexed
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762615B2 (en) * 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
CZ306810B6 (cs) * 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
IL151627A0 (en) * 2000-03-31 2003-04-10 Angiogene Pharm Ltd Divided dose therapies with vascular damaging activity
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
KR101093345B1 (ko) * 2002-02-01 2011-12-14 아스트라제네카 아베 퀴나졸린 화합물

Also Published As

Publication number Publication date
AU2004255024B2 (en) 2007-09-27
PT1653964E (pt) 2008-11-24
IL172683A0 (en) 2006-04-10
ZA200600184B (en) 2007-04-25
BRPI0412408A (pt) 2006-08-22
WO2005004872A1 (en) 2005-01-20
NZ544270A (en) 2007-09-28
GB0316127D0 (en) 2003-08-13
CA2531620A1 (en) 2005-01-20
CN1819831A (zh) 2006-08-16
MXPA06000412A (es) 2006-03-17
AU2004255024A1 (en) 2005-01-20
SI1653964T1 (sl) 2009-02-28
DE602004016754D1 (de) 2008-11-06
US20100179142A1 (en) 2010-07-15
CN100415236C (zh) 2008-09-03
EP1653964B1 (en) 2008-09-24
DK1653964T3 (da) 2009-01-05
NO20056170L (no) 2006-02-08
JP2007526888A (ja) 2007-09-20
ES2313033T3 (es) 2009-03-01
PL1653964T3 (pl) 2009-01-30
US20060167024A1 (en) 2006-07-27
KR20060033785A (ko) 2006-04-19
CA2531620C (en) 2011-09-27
EP1653964A1 (en) 2006-05-10
ATE409039T1 (de) 2008-10-15
HRP20080597T3 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
EP1971338B8 (en) Combination of zd6474 and pemetrexed
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
HK1123976A1 (en) Combination of azd2171 and pemetrexed azd2171
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
ZA200600188B (en) Combination therapy
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
IL177953A0 (en) Combination therapy including azd2171 and a taxane
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120708